A Rare Cause of Uveitis: Vemurafenib

Article Properties
Cite
Sızmaz, Selçuk, et al. “A Rare Cause of Uveitis: Vemurafenib”. Turkish Journal of Ophthalmology, vol. 48, no. 6, 2018, pp. 323-5, https://doi.org/10.4274/tjo.95914.
Sızmaz, S., Görkemli, N., Esen, E., & Demircan, N. (2018). A Rare Cause of Uveitis: Vemurafenib. Turkish Journal of Ophthalmology, 48(6), 323-325. https://doi.org/10.4274/tjo.95914
Sızmaz S, Görkemli N, Esen E, Demircan N. A Rare Cause of Uveitis: Vemurafenib. Turkish Journal of Ophthalmology. 2018;48(6):323-5.
Journal Category
Medicine
Ophthalmology
Citations
Title Journal Journal Categories Citations Publication Date
The Impact of Systemic Medications on Retinal Function Asia-Pacific Journal of Ophthalmology 2023
Uvéites médicamenteuses sous vémurafénib : à propos de deux cas Journal Français d'Ophtalmologie
  • Medicine: Medicine (General)
  • Medicine: Ophthalmology
 1 2022
Cancer Immunotherapy and Uveitis: Balancing Anti-Tumor Immunity and Ocular Autoimmunity International Ophthalmology Clinics 2022
Clinical Manifestations, Diagnosis, Treatment and Prognosis of Uveitis Induced by Anticancer Drugs: A Review of Literature

 Brain Sciences
  • Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry
  • Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry
  • Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry
 1 2022
Ocular Toxicity of Targeted Anticancer Agents Drugs
  • Medicine: Therapeutics. Pharmacology
  • Medicine: Public aspects of medicine: Toxicology. Poisons
  • Medicine: Public aspects of medicine: Toxicology. Poisons
  • Medicine: Public aspects of medicine: Toxicology. Poisons
 20 2021
Citations Analysis
Category Category Repetition
Medicine: Medicine (General)3
Medicine: Ophthalmology3
Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry1
Medicine: Therapeutics. Pharmacology1
Medicine: Public aspects of medicine: Toxicology. Poisons1
The category Medicine: Medicine (General) 3 is the most commonly referenced area in studies that cite this article. The first research to cite this article was titled Vemurafenib and was published in 2019. The most recent citation comes from a 2023 study titled The Impact of Systemic Medications on Retinal Function. This article reached its peak citation in 2022, with 3 citations. It has been cited in 9 different journals, 11% of which are open access. Among related journals, the Asia-Pacific Journal of Ophthalmology cited this research the most, with 1 citations. The chart below illustrates the annual citation trends for this article.
Citations used this article by year